Want to see CANF full AI Analyst Report?
Can-Fite BioPharma (CANF) Stock Statistics & Valuation Metrics
Total Valuation
Can-Fite BioPharma has a market cap or net worth of $5.28M. The enterprise value is -$1.48M.
- Market Cap
- $5.28M
- Enterprise Value
- -$1.48M
Share Statistics
Can-Fite BioPharma has 3,035,314 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 3,035,314
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Can-Fite BioPharma’s return on equity (ROE) is -1.77 and return on invested capital (ROIC) is -146.65%.
- Return on Equity (ROE)
- -1.77
- Return on Assets (ROA)
- -1.04
- Return on Invested Capital (ROIC)
- -146.65%
- Return on Capital Employed (ROCE)
- -1.48
- Revenue Per Employee
- 81.64K
- Profits Per Employee
- -1.98M
- Employee Count
- 5
- Asset Turnover
- 0.04
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Can-Fite BioPharma is -0.24. Can-Fite BioPharma’s PEG ratio is 0.00.
- PE Ratio
- -0.24
- PS Ratio
- 9.03
- PB Ratio
- 0.65
- Price to FCF
- -0.38
- Price to Operating Cash Flow
- -0.33
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Can-Fite BioPharma had revenue of 408.21K and earned -9.91M in profits. Earnings per share was -0.08.
- Revenue
- 408.21K
- Gross Profit
- 384.02K
- Operating Income
- -10.03M
- Pretax Income
- -9.91M
- Net Income
- -9.91M
- EBITDA
- -10.00M
- Earnings Per Share (EPS)
- -0.08
Cash Flow
In the last 12 months, operating cash flow was -9.51M and capital expenditures -2,000, giving a free cash flow of -9.51M billion.
- Operating Cash Flow
- -9.51M
- Free Cash Flow
- -9.51M
- Free Cash Flow per Share
- -5.13
Dividends & Yields
Can-Fite BioPharma pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -260.56%
- Earnings Yield
- -302.13%
Stock Price Statistics
- Beta
- 1.24
- 52-Week Price Change
- -80.33%
- 50-Day Moving Average
- 2.24
- 200-Day Moving Average
- 3.20
- Relative Strength Index (RSI)
- 24.37
- Average Volume (3m)
- 376.20K
Important Dates
Can-Fite BioPharma upcoming earnings date is Apr 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Sep 08, 2026
- Next Earnings Date
- Apr 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Can-Fite BioPharma as a current ratio of 3.46, with Debt / Equity ratio of 1.27%
- Current Ratio
- 3.46
- Quick Ratio
- 3.46
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.55
- Interest Coverage Ratio
- -710.72
Taxes
In the past 12 months, Can-Fite BioPharma has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Can-Fite BioPharma EV to EBITDA ratio is -0.07, with an EV/FCF ratio of -0.08.
- EV to Sales
- 1.77
- EV to EBITDA
- -0.07
- EV to Free Cash Flow
- -0.08
- EV to Operating Cash Flow
- -0.08
Balance Sheet
Can-Fite BioPharma has $7.04M in cash and marketable securities with $49.00K in debt, giving a net cash position of $6.99M billion.
- Cash & Marketable Securities
- $7.04M
- Total Debt
- $49.00K
- Net Cash
- $6.99M
- Net Cash Per Share
- $2.30
- Tangible Book Value Per Share
- $1.31
Margins
Gross margin is 100.00%, with operating margin of -2402.96%, and net profit margin of -2358.77%.
- Gross Margin
- 100.00%
- Operating Margin
- -2402.96%
- Pretax Margin
- -2358.77%
- Net Profit Margin
- -2358.77%
- EBITDA Margin
- -2402.47%
- EBIT Margin
- -2402.96%
Analyst Forecast
The average price target for Can-Fite BioPharma is $8.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $8.00
- Price Target Upside
- 393.83% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- ―
- AI Score
- 40
